S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:OCS

Oculis (OCS) Stock Price, News & Analysis

$11.90
-0.10 (-0.83%)
(As of 04/17/2024 ET)
Today's Range
$11.90
$12.05
50-Day Range
$10.81
$12.78
52-Week Range
$9.05
$14.50
Volume
32,580 shs
Average Volume
38,558 shs
Market Capitalization
$481.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.29

Oculis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
146.1% Upside
$29.29 Price Target
Short Interest
Healthy
0.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Oculis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.75) to ($2.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

570th out of 913 stocks

Biotechnology Industry

38th out of 60 stocks

OCS stock logo

About Oculis Stock (NASDAQ:OCS)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

OCS Stock Price History

OCS Stock News Headlines

Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
See More Headlines
Receive OCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/17/2024
Next Earnings (Estimated)
6/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OCS
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.29
High Stock Price Target
$35.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+146.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$980,000.00
Book Value
$2.87 per share

Miscellaneous

Free Float
N/A
Market Cap
$481.95 million
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Riad Sherif M.B.A. (Age 56)
    M.D., CEO & Director
  • Ms. Sylvia Cheung (Age 49)
    Chief Financial Officer
  • Mr. Weibo Ding (Age 53)
    Global COO & GM of China
  • Dr. Ramin Tadayoni M.D.
    Ph.D., Chief Scientific Officer
  • Ms. Virginia R. Dean (Age 57)
    Chief Human Resources Officer
  • Dr. Bastian Dehmel M.D. (Age 53)
    Chief Development Officer
  • Mr. Páll Ragnar Jóhannesson (Age 42)
    Chief Business Officer
  • Ms. Rebecca Weil
    Chief Commercial Officer
  • Dr. Snehal Shah Pharm.D.
    President of Research & Development

OCS Stock Analysis - Frequently Asked Questions

Should I buy or sell Oculis stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCS shares.
View OCS analyst ratings
or view top-rated stocks.

What is Oculis' stock price target for 2024?

9 analysts have issued 1-year target prices for Oculis' shares. Their OCS share price targets range from $23.00 to $35.00. On average, they anticipate the company's share price to reach $29.29 in the next year. This suggests a possible upside of 146.1% from the stock's current price.
View analysts price targets for OCS
or view top-rated stocks among Wall Street analysts.

How have OCS shares performed in 2024?

Oculis' stock was trading at $11.23 at the start of the year. Since then, OCS shares have increased by 6.0% and is now trading at $11.90.
View the best growth stocks for 2024 here
.

Are investors shorting Oculis?

Oculis saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 32,400 shares, a drop of 31.4% from the March 15th total of 47,200 shares. Based on an average daily volume of 37,700 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.2% of the shares of the company are short sold.
View Oculis' Short Interest
.

When is Oculis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 17th 2024.
View our OCS earnings forecast
.

How were Oculis' earnings last quarter?

Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.28 million.

How do I buy shares of Oculis?

Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCS) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners